A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Sponsor
Huashan Hospital
Study ID
NCT04520646
Status
Unknown

Conditions

  • Acromegaly
  • Cardiomyopathies

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin — DRUG
    empagliflozin of 10mg/day is added on the basis of primary care

Study Details

Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient medicine is available for acromegalic cardiomyopathy until now and there were limited studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients and independent of blood glucose control. We planed to evaluate the structure of heart by MRI before and after 6 months treatment with empagliflozin in acromegalic patients to investigate the effect of empagliflozin on acromegalic cardiomyopathy.

Key Dates

Start date
Sep 1, 2020
Status verified
Aug 2020
Primary completion
Aug 31, 2021
Completion
Aug 31, 2022

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: empagliflozin
    empagliflozin is added on the basis of the original treatment

Primary Outcome Measure

Left ventricular mass index [ Time Frame: 6 months ]

Central Contacts

Related Studies